small cell lung cancer

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

Amgen's BiTE for lung cancer backed for EU approval

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

Digital

BIO-Europe Spring interview with Dr Olga Nissan

On collaboration, computational chemistry, and cutting-edge ...

Dr Olga Nissan, vice president of business development at Evogene discusses collaboration with Google Cloud & generative design of small molecules.

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

Boehringer advances duo for aggressive cancers into phase 3

Amgen's BiTE for lung cancer backed for EU approval

On collaboration, computational chemistry, and cutting-edge ...

ESMO25: Patient-centric oncological futures with Boehringer ...

Jazz, Roche combo cleared by FDA for lung cancer

Imfinzi becomes first NHS drug for aggressive lung cancer

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Discover a new era of healthcare panel engagement: Grounded ...

small cell lung cancer

Editor's Picks